MedPath

Assessing the vaginal tablet - Misoprostol and Placebo(drug without any action) for dilatation of cervix before hysteroscopy(procedure where camera inserted into uterus through vagina to carry out small surgeries) using small size instrument-mini resectoscope

Not Applicable
Conditions
Health Condition 1: N998- Other intraoperative and postprocedural complications and disorders of genitourinary system
Registration Number
CTRI/2022/11/047611
Lead Sponsor
Jawaharlal Institute of Postgraduate Medical Education and Research
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Pre menopausal women and women with age >18 years scheduled for Operative hysteroscopic procedures with Mini resectoscope.

Exclusion Criteria

Known case of Cervical incompetence and stenosis

Contraindication to Misoprostol use like history of severe asthma, glaucoma, preexisting cardiac disease, hypertension or renal failure.

Significant uterovaginal prolapse precluding the administration of vaginal tablets.

Pelvic inflammatory disease.

Genital tract malignancy like Ca cervix, Vulval carcinoma.

Pregnancy.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare the pre- dilatation cervical width following vaginal Misoprostol Or vaginal Placebo instillation in women undergoing Operative hysteroscopy using a mini resectoscope-21FTimepoint: During Surgery
Secondary Outcome Measures
NameTimeMethod
To compare the need for further cervical dilatation, complications and side effects following vaginal Misoprostol Or vaginal Placebo instillation in women undergoing Operative hysteroscopy using a mini resectoscope-21FTimepoint: During surgery and 1 hour after surgery.
© Copyright 2025. All Rights Reserved by MedPath